
|Videos|May 24, 2017
Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC
Author(s)Axel Grothey, MD
Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).
Advertisement
Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5



































